Develops stem cell therapies for inflammatory and autoimmune diseases, and sells stem cell products, research materials and skin-care products to clinics, researchers and consumers.
10-K for FY2025, filed Feb 13, 2026We are an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders, with an ancillary focus in the…View ↗
Our lead investigational product candidate is our cell-based therapy product (“AlloRx Stem Cell therapy”), which is based on our…View ↗
While our primary business strategy is to become a leading regenerative medicine and cellular therapy company through the development and…View ↗
In addition to selling our clinical grade formulation of MSC-Gro to a single customer in Australia, as further described above, we sell…View ↗
We supply AlloRx Stem Cells to certain foreign clinics and medical centers that use AlloRx Stem Cells to conduct open-label…View ↗
Through InfiniVive MD, our wholly-owned subsidiary, we develop and sell topical cosmetic conditioned media and exosome-containing serums…View ↗
Customers pay for products when they ship. For consulting work, payment is tied to reaching contractual milestones.
10-K for FY2025, filed Feb 13, 2026
$2.1M
10-K for FY2025, filed Feb 13, 2026
$2.1M ↗
The company sells stem cell products and research materials directly to biopharmaceutical institutions, university labs and clinics, and supplies AlloRx Stem Cells to foreign clinics and medical centers. Its cosmetic products are sold to surgeons, aestheticians and consumers, while Fitore supplements are sold online.
10-K for FY2025, filed Feb 13, 2026In addition to selling our clinical grade formulation of MSC-Gro to a single customer in Australia, as further described above, we sell…View ↗
We supply AlloRx Stem Cells to certain foreign clinics and medical centers that use AlloRx Stem Cells to conduct open-label…View ↗
Through InfiniVive MD, our wholly-owned subsidiary, we develop and sell topical cosmetic conditioned media and exosome-containing serums…View ↗
Fitore product sales online: Includes internet sales, via the Fitore Nutrition website, of dietary supplements called Stemulife, Spectrum+…View ↗
InfiniVive product sales: InfiniVive, via call-in orders, sells exosomes and daily cosmetic serum.View ↗
10-K for FY2025, filed Feb 13, 2026
During the years ended October 31, 2025 and 2024, 2% and 2% respectively, of the Company’s total revenues were derived from sales to an…View ↗
No. It lost $10.9M in FY2025.
10-K for FY2025, filed Feb 13, 2026
−$5MView ↗
10-K for FY2025, filed Feb 13, 2026
−$10.9MView ↗
10-K for FY2025, filed Feb 13, 2026
−$2.5MView ↗
Shrinking. Revenue fell 38% in 3 years, from $3.3M in FY2022 to $2.1M in FY2025, about 15% a year.
Competes with Athersys, BrainStorm Cell Therapeutics, Celularity, Corestem, Coya Therapeutics, Fate Therapeutics, Healios, Longeveron, Medipost, Mesoblast, Pluristem Therapeutics, SanBio, Stemedica Cell Technologies, Axcella Health, GlaxoSmithKline, Tonix Pharmaceuticals, Vir Biotechnology, and Neuren Pharmaceuticals
10-K for FY2025, filed Feb 13, 2026Name Corporate Headquarters Clinical stage pipeline indication(s) Athersys, Inc. U.S. Ischemic stroke; ARDS; GvHD; Acute Myocardial…View ↗
Loading...
